Why a non-invasive prenatal test?
Non-invasive prenatal tests can prevent the need for about 98% of invasive tests in patients at risk for T211.
* The current standard for detecting prenatal chromosomal alterations requires
the use of invasive techniques (amniocentesis and chorionic villus biopsy), which carry a risk between 0.5%-2% of spontaneous abortion.
* NACE® provides reliable information which avoids the need for unnecessary invasive techniques.
Coverage of the NACE® test for single pregnancies ordered by their importance
According to data from the 2012 European Registry for Prenatal Diagnosis2, abnormalities
in chromosomes 21, 18, and 13 represent 71% of all chromosomal alterations detected.
Detection rate according to the type of screening
Type of screening
Extended combined screening**
* Includes maternal age, nuchal translucency measurement, and the detection of the PAPP-A and free B-HCG biochemical markers.
** Includes other ultrasound markers: nasal bone absence, assessment of the ductus venosus, and tricuspid blood flow. (FP = false positives).
As per PCPNDT guidelines, sexing status of the analyzed sample is never revealed in the report neither in any other way to the couple or clinician.